

This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city, or area of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as "developed", "industrialized" and "developing" are intended for statistical convenience and do not necessarily express a judgment about the state reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. The opinions, statistical data and estimates contained in signed articles are the responsibility of the author(s) and should not necessarily be considered as reflecting the views or bearing the endorsement of UNIDO. Although great care has been taken to maintain the accuracy of information herein, neither UNIDO nor its Member States assume any responsibility for consequences which may arise from the use of the material.

This document may be freely quoted or reprinted but acknowledgement is requested

PHARMACEUTICAL INDUSTRY

IN SUB-SAHARAN AFRICA

FOR PROMOTING
PHARMACEUTICAL
PRODUCTION
-IN AFRICA-





UNITED NATIONS
INDUSTRIAL DEVELOPMENT ORGANIZATION

ACKNOWLEDGEMENTS

This document is a main output of the project "Devising practical approaches for mobilizing capital and transfer of technology for Africa's pharmaceutical industry", funded by the Federal Ministry for Economic Cooperation and Development of Germany. The guidance in this document is based on the findings of, and deliberations at, the Expert Group Meeting (EGM) "Practical Approaches for Government Incentives, Mobilizing Affordable Financing and Access to Technology for the Pharmaceutical Industry in Africa" held in Vienna, Austria on 27-29 September 2017. The completion of the document would not have been possible without the contributions of Geoffrey Banda, Sudip Chaudhuri, Luxin Chen, Perviz Dhanani, Natalia Donde, Shahid Hasan, Kristopher Howard, Nabeela Khan, Wilko von Kluechtzner, Maureen Mackintosh, Nazeem Mohamed, Emmanuel Mujuru, Sarah Nam, Martin Nicholson, Duncan Onyango, Rabbur Reza, Bertrand Talbotier, Wilhelm Volk and Alastair West. Sudip Chaudhuri summarized the EGM and laid the basis for this guide. Geoffrey Banda contributed especially to Chapter 8 "How to stimulate access to finance for the pharmaceutical industry" and Maureen Mackintosh to Chapter 4 "How to improve the policy framework for pharmaceutical manufacturing".

The lead author was Simon White. Nadine Vohrer, Industrial Development Expert, UNIDO led and coordinated the completion of the document. The overall management of the project rested with Juergen Reinhardt, Senior Industrial Development Officer, Investment Promotion Division, Department of Trade, Investment and Innovation, UNIDO. The intervention formed part of UNIDO's long-time support for promoting local pharmaceutical production in developing and least developed countries, with a focus on sub-Saharan Africa. For more information see:

https://www.unido.org/pharmaceuticals

https://www.unido.org/sites/default/files/files/2019-01/Boosting_ Pharmaceutical Production.pdf



TABLE OF CONTENTS

Table of co	ontents	vi		
List of abb	reviations	vii		
Executive S	Summary	viii		
1.	Introduction	1		
1.1	Challenges and opportunities for pharmaceutical production in Africa	1		
1.2	Purpose of the guide	2		
1.3	Intended readers	2		
1.4	Organization of the document	2		
Part 1:	The context and framework for pharmaceutical production in Africa	3		
2.	Pharmaceutical production in sub-Saharan Africa			
2.1	Africa's development challenge			
2.2	Health security and pharmaceutical production in Africa	6		
2.3	Industrial development and pharmaceutical production in sub-Saharan Africa	8		
2.4	The state of the pharmaceutical industry in Africa	9		
3	Key challenges to transforming the pharmaceutical sector	15		
Part 2:	Policy and strategic advice for pharmaceutical production in Africa	17		
4	How to improve the policy framework for pharmaceutical manufacturing	18		
4.1	Challenges	20		
4.2	Guidance	23		
5	How to improve competitiveness in the pharmaceutical sector	26		
5.1	Challenges	28		
5.2	Guidance	30		
6	How to improve access to new and more profitable markets	34		
6.1	Challenges	36		
6.2	Guidance	37		
7	How to improve quality and develop the product portfolio	42		
7.1	Challenges	44		
7.2	Guidance	48		
8	How to stimulate access to finance for the pharmaceutical industry	52		
8.1	Challenges	54		
8.2	Guidance	60		
9.	List of references	66		

LIST OF ABBREVIATIONS

ACT	Artemisinin-based combination therapy	PMPA BP	Business Plan for the accelerated implementation of the Pharmaceutical Manufacturing Plan for Africa	
API	Active pharmaceutical ingredient			
AIDA	Accelerated Industrial Development of Africa	QMS	Quality management system	
AIDS	Acquired Immune Deficiency Syndrome	R&D	Research and development	
AMRH	African Medicines Regulatory Harmonization	RPMPOA	EAC Regional Pharmaceutical Manufacturing Plan of Action	
ARV	Antiretroviral (drug)	SDGs	Sustainable Development Goals	
AU	African Union	SME	Small and medium enterprise	
CTD	Common technical document			
DFI	Development finance institution	SSA	Sub-Sahara Africa	
EAC	East African Community	TRIPS	Trade-related intellectual property rights	
EBITDA	Earnings before interest tax	UN	United Nations	
LBITDA	depreciation and amortization	n and amortization UNAIDS Joir	Joint United Nations Programme on HIV/	
ECOWAS	Economic Community of West African States	UNCTAD		
ERPP	ECOWAS Regional Pharmaceutical Plan		·	
FDI	Foreign direct investment	UNICEF United Nations International Children's Emergency Fund		
GIZ	Deutsche Gesellschaft für Internationale Zusammenarbeit	UNIDO	United National Industrial Development Organization	
GMP	Good manufacturing practice	USD	United States Dollar	
HIV	Human immunodeficiency virus	VAT	Value Added Tax	
IDDA	Industrial Development Decade for Africa	VC	Venture Capital	
MCF	Medical Credit Fund	WHO	World Health Organization	
NEPAD	New Partnership for Africa's Development	WTO	World Trade Organization	
NMRA	National medicines regulatory authority			
PE	Private equity			
PMPA	Pharmaceutical Manufacturing Plan for Africa (African Union)			

EXECUTIVE SUMMARY

There is now a wide-ranging consensus that local pharmaceutical production in sub-Saharan Africa in close proximity to where medicines are needed can reduce dependence and improve health outcomes for the population. Many African governments, regional economic communities and the African Union have recognized the need for active support to the development of the sector if these benefits are to be realized. However, concrete action on the ground has remained hesitant and piecemeal to date.

This document contains advice for government policy makers, the private sector especially pharmaceutical manufacturers in sub-Saharan African countries, development partners and (development) finance institutions on how to promote pharmaceutical production. The guide focuses on the key areas competitiveness, market access, technology and access to finance. It further proposes a path of how governments could embark on and steer a policy development process as well as giving guidance on policy interventions. The document especially emphasizes the interconnectedness of key intervention areas and recommends that promotional measures from key areas should be combined to increase impact.

OVERVIEW OF GUIDANCE

HOW TO IMPROVE
POLICY FRAMEWORK
FOR THE PHARMACEUTICAL
MANUFACTURING

4.2.1

HOW TO IMPROVE

COMPETITIVENESS
IN THE PHARMACEUTICAL
SECTOR

Assess local conditions and industry

5.2.1 Improve the investment climate and

预览已结束,完整报告链接和.

https://www.yunbaogao.cn/report/index/report?re